Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis
Efgartigimod has been recognised as a valuable option for gMG AChR+ treatment in Spain by a multidisciplinary panel of experts through the application of MCDA, receiving higher scores compared with ravulizumab, zilucoplan, and rozanolixizumab.
Authors
- Alicia Gil
- Celia Martín Machín
- Antonio Guerrero
- Francisco J. Toja-Camba
- María R. Abad
- Eva Martínez
- José M. Serra
- Jose L. Trillo
- Elena Cortés-Vicente
- Carmina Díaz
Institutions
- Hospital de Sant Pau (ES)
- Hospital Clínico San Carlos (ES)
- Hospital Universitario Virgen Macarena (ES)
- Complejo Hospitalario Universitario de Santiago (ES)
- Oblikue Consulting (Spain) (ES)
- Hospital Universitario Miguel Servet (ES)
- Hospital Universitario de La Princesa (ES)
- Hospital General Universitario de Alicante Doctor Balmis (ES)
- INCLIVA Health Research Institute (ES)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2026-01-27
- DOI
- https://doi.org/10.1007/s12325-026-03490-x
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00